News

BioMarin Pharmaceutical Publishes Follow-Up Data for Hemophilia A Gene Therapy Phase I/II Study

BioMarin Pharmaceutical Publishes Follow-Up Data for Hemophilia A Gene Therapy Phase I/II Study

BioMarin announced the publication in the New England Journal of Medicine of a peer-reviewed article covering up to three years of follow-up data from an ongoing phase II/II study evaluating valoctocogene roxaparvovec, an investigational AAV-based gene therapy for severe hemophilia A. The results demonstrate a "sustained, clinically relevant benefit" to patients from a single infusion of valoctocogene roxaparvovec. With our extensive temperature-controlled storage, packaging, and courier capabilities, Yourway is well equipped to support clinical trials for gene therapies and other advanced therapies.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?